CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metabolix,
Inc. (NASDAQ: MBLX), a bioscience company focused on developing
clean, sustainable solutions for plastics, chemicals and energy, today
announced that it has appointed Stephen J. Large to its board of
directors. Mr. Large brings more than 25 years of experience in the
global chemicals industry to the Company's board. The appointment is
effective as of Monday, March 26, 2012.
"As a veteran of the global chemicals industry, Steve brings both
operational expertise and deep market knowledge to the board," said
Richard P. Eno, President and CEO of Metabolix. "We look forward to
Steve's insight as we execute our business strategy around the delivery
of sustainable, differentiated alternatives to conventional plastics and
chemicals."
Since 2008, Mr. Large has served as president and chief executive
officer of Schenectady, New York-based SI Group, Inc., a private global
company specializing in the development and manufacturing of chemical
intermediates. Mr. Large also previously served SI Group as president
and chief operating officer. Prior to joining SI Group, Mr. Large spent
15 years with Minnesota-based H.B. Fuller, an adhesives, sealants and
coatings company, in numerous global roles, including his most recent
position as president of the specialty group. Mr. Large also served as
general manager and director of South African chemical manufacturer T&C
Chemical Industries PTY Ltd. He holds a bachelor's degree in polymer
science and technology from the Plastics and Rubber Institute at
Manchester Polytechnic in the United Kingdom.
"A transformation of the global chemicals industry will gain momentum
over the coming years as brand owners and consumers increasingly seek
‘green' alternatives to conventional plastics and chemicals from fossil
fuels. Metabolix's technology platforms and product offerings are
industry leading and uniquely suited to the trends emerging in the
market for biobased plastics and chemicals," said Mr. Large. "I look
forward to working with the board of directors and Metabolix to capture
the commercial potential of this growing market."
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience
company focused on providing sustainable solutions for the world's needs
for plastics, chemicals and energy. The Company is taking a systems
approach, from gene to end product, integrating sophisticated
biotechnology with advanced industrial practice. Metabolix is developing
biosourced industrial chemicals and plastics, as well as a proprietary
platform technology for co-producing plastics, chemicals and energy from
crops.
For more information, please visit www.metabolix.com.
(MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this release do
not constitute guarantees of future performance. Investors are cautioned
that statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding Mr.
Large's potential contribution to Metabolix, the future of the global
chemicals industry, expectations for commercialization of Metabolix
products and technology, and executing our business strategy, constitute
forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated and are detailed in
Metabolix's filings with the Securities and Exchange Commission
including the 2011 10-K filed March 12, 2012. Metabolix assumes no
obligation to update any forward-looking information contained in this
press release or with respect to the announcements described herein.
Media:
Metabolix
Lynne Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz
MSL Boston
Keith Giannini or Kirsten Swenson, 781-684-0770
metabolix@schwartzmsl.com
or
Investors:
ICR
James
Palczynski, 203-682-8229
james.palczynski@icrinc.com
Source: Metabolix, Inc.
News Provided by Acquire Media